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N-glycosylation site occupancy in serum glycoproteins using
multiple reaction monitoring liquid chromatography-mass
spectrometry
Abstract
Congenital disorders of glycosylation (CDGs) are a family of N-linked glycosylation defects associated
with severe clinical manifestations. In CDG type-I, deficiency of lipid-linked oligosaccharide assembly
leads to the underoccupancy of N-glycosylation sites on glycoproteins. Although the level of residual
glycosylation activity is known to correlate with the clinical phenotype linked to individual CDG
mutations, it is not known whether the degree of N-glycosylation site occupancy by itself correlates with
the severity of the disease. To quantify the extent of underglycosylation in healthy control and in CDG
samples, we developed a quantitative method of N-glycosylation site occupancy based on multiple
reaction monitoring LC-MS/MS. Using isotopically labeled standard peptides, we directly quantified the
level of N-glycosylation site occupancy on selected serum proteins. In healthy control samples, we
determined 98-100% occupancy for all N-glycosylation sites of transferrin and alpha(1)-antitrypsin. In
CDG type-I samples, we observed a reduction in N-glycosylation site occupancy that correlated with the
severity of the disease. In addition, we noticed a selective underglycosylation of N-glycosylation sites,
indicating preferential glycosylation of acceptor sequons of a given glycoprotein. In transferrin, a
preferred occupancy for the first N-glycosylation site was observed, and a decreasing preference for the
first, third, and second N-glycosylation sites was observed in alpha(1)-antitrypsin. This multiple reaction
monitoring LC-MS/MS method can be extended to multiple glycoproteins, thereby enabling a
glycoproteomics survey of N-glycosylation site occupancies in biological samples.
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Abbreviations 
 
CDG congenital disorders of glycosylation 
cps counts per second 
HFI hereditary fructose intolerance 
MRM multiple reaction monitoring 
MRM-LC-MS/MS multiple reaction monitoring liquid chromatography tandem mass 
spectrometry 
PNGaseF peptide N-glycanase F 
QTRAP quadrupole ion trap mass spectrometer 
XIC extracted ion chromatogram 
 
 at SM
AC Consortium
 - University of Zürich on February 9, 2010 
w
w
w
.m
cponline.org
D
ow
nloaded from
 
 3
Summary 
Congenital disorders of glycosylation (CDG) are a family of N-linked glycosylation defects 
associated with severe clinical manifestations. In CDG type-I, deficiency of lipid-linked 
oligosaccharide assembly lead to the under-occupancy of N-glycosylation sites on glycoproteins. 
Although the level of residual glycosylation activity is known to correlate with the clinical 
phenotype linked to individual CDG mutations, it is not known whether the degree of N-
glycosylation site occupancy by itself correlates with the severity of the disease. To quantify the 
extent of underglycosylation in healthy control and in CDG samples, we developed a quantitative 
method of N-glycosylation site occupancy based on multiple reaction monitoring LC- MS/MS. 
Using isotopically labeled standard peptides, we directly quantified the level of N-glycosylation 
site occupancy on selected serum proteins. In healthy control samples, we determined 98-100% 
occupancy for all N-glycosylation sites of transferrin and α1-antitrypsin. In CDG type-I samples, 
we observed a reduction in N-glycosylation site occupancy, which correlated with the severity of 
the disease. In addition, we noticed a selective underglycosylation of N-glycosylation sites, 
indicating preferential glycosylation of acceptor sequons of a given glycoprotein. In transferrin, a 
preferred occupancy for the first N-glycosylation site was observed and a decreasing preference 
for the first, third and second N-glycosylation site was observed in α1-antitrypsin. This multiple 
reaction monitoring LC-MS/MS method can be extended to multiple glycoproteins, thereby 
enabling a glyco-proteomic survey of N-glycosylation site occupancies in biological samples. 
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Introduction 
In human, disturbances in the biosynthesis of glycoconjugates lead to diseases with 
heterogeneous biochemical and clinical characteristics(1). Deficiencies in the biosynthesis of 
serine- or threonine-linked (O-linked), asparagines-linked (N-linked), 
glycosylphosphatidylinositol and glycosphingolipid glycans have been described(2-5). Inherited 
deficiencies in the N-glycosylation biosynthetic pathway are referred to as congenital disorders 
of glycosylation (CDG). CDGs represent multi-organ diseases involving central and peripheral 
nervous defects and are often associated with endocrine and coagulation disorders(6). The 
heterogeneous symptoms associated to CDG and the structural diversity of glycoconjugate 
render the identification of glycosylation defects a difficult task. After initial clinical suspicion of 
CDG, the serum glycoprotein transferrin serves as a biomarker for possible defects of N-
glycosylation. The integrity of transferrin N-glycosylation is tested by isoelectric focusing 
electrophoresis, Western blot analysis and by MS measurements of the purified glycoprotein(7-
9). Deficiencies of N-glycosylation site occupancy are classified as CDG type-I (CDG-I), 
whereas defects of N-glycan trimming and elongation are classified as CDG type-II (CDG-
II)(10). 
To date, 12 distinct genetic defects, which affect the N-glycosylation output to different levels, 
have been identified as cause of CDG-I. Mutations in the phosphomannomutase-2 gene represent 
the most frequent form of CDG-I. The level of residual enzymatic activity associated to 
individual mutations in the phosphomannomutase-2 gene has been correlated with the severity of 
the clinical presentations(11). However, the exact degree of protein underglycosylation in CDG-I 
has not been determined yet, and it is unclear whether the degree of underglycosylation directly 
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relates to the severity of the disease. Also, the degree of N-glycosylation site occupancy found in 
healthy individuals has not been defined yet. 
To better understand the functional significance of N-glycosylation in humans, a precise measure 
for the glycosylation site occupancy in healthy and in CDG-related conditions is necessary. In 
proteomics, the most widely applied experiment for the determination of peptide sequences relies 
on product ion scanning mass spectrometry (MS/MS). Precursor ions of selected peptides are 
selected in a first mass analyzer, fragmented in a collision cell and the generated product ion 
fragments are scanned in a second mass analyzer. Triple quadrupole mass spectrometers are 
particularly suitable for quantitative determinations of changes in serum protein levels. These 
instruments allow multiple reaction monitoring (MRM) experiments, a sequential selection of 
peptide specific precursor ions in the first mass analyzer together with a characteristic fragment 
ion in the second mass analyzer upon fragmentation in the collision cell. Transitions of precursor 
to fragment ions lead to signals in the detector and can be recorded as a function of time during 
chromatographic elution. Additionally, the sequence of eluting peptides can be confirmed by the 
acquisition of corresponding product ion spectra. The selectivity of the MRM transitions together 
with short scan times for each transition allow for sensitive, quantitative analyses of complex 
samples(12, 13). 
In the present study, we describe a MRM LC-MS/MS approach to quantify the N-glycosylation 
site occupancy of the serum glycoproteins transferrin and α1-antitrypsin. We analyzed 28 serum 
samples and quantified glycosylation site occupancies in healthy and in disease related samples. 
For the first time, we found a clear correlation in CDG-I between the degree of N-glycosylation 
site occupancy and the severity of the disease. 
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Experimental Procedures 
Isoelectric focusing gel electrophoresis 
Serum transferrin was saturated for 30 min with ferric citrate (0.4 mM) in the presence of sodium 
hydrogen carbonate (20 mM) and separated on a rehydrated Immobiline DryPlate gel (GE 
Healthcare) with a pH range of 4.0-7.0 using the Phast-System (Amersham Biosciences). 
Transferrin was visualized by gel immunoprecipitation using polyclonal rabbit anti-human 
transferrin antibodies (DakoCytomation). The antibody solution was directly applied onto the gel 
and incubated for 1h. To remove excess of antibodies and non-bound proteins, the gel was 
washed over night in 0.9% NaCl, followed by fixation and staining with PhastGel Blue R (GE 
Healthcare) according to the manufacture protocol. 
 
Immuno-affinity enrichment of glycoproteins from human serum 
Serum glycoproteins were purified with a custom made HU-6 multiple affinity removal system 
column (MARS column, 4.6 x 50 mm, Agilent Technologies), targeting transferrin, IgG and α1-
antitrypsin. The purification was performed from 5 μl human serum using the buffers and 
protocol recommended by the manufacturer. The glycoproteins were eluted into 1 ml fractions 
and the elution was monitored by UV absorption at 280 nm. 
 
Proteolytic digestion and glycopeptide labeling 
The proteins in the collected fractions were precipitated with TCA, pooled with reduction buffer 
(0.57 M Tris-HCl, pH 8.5, 50 mM DTT) to a final volume of 250 μl. The proteins were reduced 
at 80 °C for 5 min, cooled to room temperature and 63 μl of 1 M iodoacetamide in water were 
added. The samples were incubated for 40 min at room temperature in the dark and the alkylated 
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 7
proteins were desalted by TCA precipitation. The reduced and alkylated samples were re-
dissolved in 50 μl of 20 mM ammonium bicarbonate, 10% ACN containing Asp-N and trypsin 
(0.5 μg each, Roche) and digested for 16 h at 37 °C. The digests were heat inactivated at 80 °C 
for 5 min. Then, 0.5 μmol EDTA, 100 μg aprotinin, 8 pmol of the standard peptides 
corresponding to the transferrin N-glycosylation sites (TFP1NK, TFP1NKS, TFP1DK, 
TFP1DKS, TFP2NVT, TFP2DVT, see Table 1) and 2 pmol each of the standard peptides 
corresponding to the α1-antitrypsin N-glycosylation sites (ATP1N, ATP1D, ATP2N, ATP2D, 
ATP3N, ATP3D, see Table 1) were added. The samples were lyophilized for at least 16 h. The 
samples were re-dissolved in 20 mM ammonium bicarbonate in 95 atom% H218O (Sigma) and 
1.5 units peptide N-glycanase F (PNGaseF, Roche) reconstituted with 95 atom% H218O were 
added. The samples were digested for 8 h at 37 °C, heat inactivated at 80 °C for 5 min and stored 
at -20 °C until further use. 
 
Mass spectrometry 
An Applied Biosystems QTRAP 3200 LC-MS/MS system, equipped with a NanoSpray II ion 
source and an Eksigent nanoLC-2D system was used. The sample reaction mixture (2 to 10 μl) 
was filtered with 0.22 μm centrifugal filter devices, adjusted to 20 μl 0.1% formic acid and 2% 
ACN and loaded on an LC Packings C18 PepMap 100 trap column (300 μm i.d. x 5 mm, 
Dionex). The trap column was washed with 60 μl loading buffer and switched in line to a 
ProteoPep2 column (75 μm i.d. x 15 cm, C18, IntegraFrit, New Objective). A binary gradient at 
250 nl/min was applied. Buffer A was 0.1% formic acid and buffer B was 80% ACN containing 
0.1% formic acid. Buffer B was held at 14% for 3 min, increased to 54% over 102 min, to 100% 
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over 8 min, held at 100% for 12 min, decreased to 14% over 12 min and the column was re-
equilibrated at 14% buffer B for 16 min. MRM transitions and product ion scans were acquired 
sequentially and the LC gradient was divided into three acquisition periods. The first 23 min 
MRM transitions and product ion scans corresponding to the second, C-terminal transferrin N-
glycosylation site were recorded (TFP2NVT, TFP2DVT and corresponding sample peptides). 
During the second period data corresponding to the first N-terminal transferrin N-glycosylation 
site were acquired for 25 min (TFP1NK, TFP1NKS, TFP1DK, TFP1DKS and corresponding 
sample peptides). During the third period data corresponding to the α1-antitrypsin N-
glycosylation sites were acquired until completion of the LC run (ATP1N, ATP1D, ATP2N, 
ATP2D, ATP3N, ATP3D and corresponding sample peptides). Fragment ions and fragmentation 
settings for the sample derived peptides were set according to the MRM transitions established 
for the standard peptides (Table 1). The average counts per second (cps) of the sample peptide 
peaks were divided by the average cps of the standard peptide and multiplied with the amount of 
standard peptides added to the sample preparation. The sum of the amounts of previously 
glycosylated and unglycosylated peptides was set to 100%. The percentage of site occupancy 
was calculated as the part of previously glycosylated, i.e. PNGaseF sensitive peptides. 
Results 
The serum glycoprotein transferrin is the most widely used biomarker for the clinical diagnosis 
of CDG-I and -II. Normal serum transferrin typically contains two sialylated, biantennary 
complex type N-glycans attached to the glycosylation sites at Asp413 and Asp611(14). Serum 
samples from CDG-I, CDG-II, hereditary fructose intolerance (HFI) and healthy individuals 
were analyzed by transferrin isoelectric focusing gel electrophoresis and the typical deviations of 
the band pattering of CDG sera from the healthy controls could be observed (Fig. 1). A major 
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 9
band corresponding to tetrasialylated, fully glycosylated transferrin was observed in control 
samples. In CDG sera, undersialylation was detected with more intense bands corresponding to 
tri-, di-, mono- and asialylated transferrin. In CDG-II, this pattern can be explained by altered 
trimming and elongation of transferrin N-glycan structures, which leads to decreased transfer of 
terminal sialic acid. In CDG-I, decreased N-glycosylation site occupancy results in the 
undersialylation as observed in the transferrin isoelectric focusing gel (Fig. 1). In HFI the 
metabolite fructose-1-phosphate accumulates in the liver, which leads to inhibitory effects in 
early steps of N-glycosylation biosynthesis. Therefore, HFI can be considered as a secondary 
CDG syndrome and CDG-I typical patterns are observed in transferrin isoelectric focusing gel 
electrophoresis(15). Polypeptide polymorphisms of transferrin also lead to altered gel patterning, 
which can be revealed by sialidase treatment prior isoelectric focusing electrophoresis. 
 
Figure 1 
 
To precisely measure the N-glycosylation site occupancy in healthy as well as in pathological 
conditions, sera from 17 CDG patients, 1 alcohol abuse patient, 1 HFI patient and 9 sera from 
healthy individuals were selected for analysis. The serum of an alcohol abuse patient was 
included as a positive control. Alcohol abuse leads to reduced N-glycosylation site occupancy of 
transferrin, thus mimicking CDG-I(16). The samples were subjected to glycoprotein purification 
using a custom made multiple affinity column directed against human transferrin, α1-antitrypsin 
and IgG. The reduced and alkylated proteins were digested with a combination of trypsin and 
Asp-N and isotopically labeled standard peptides were added(17) (Table 1). 
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 10
Table 1 
 
Table 2 
 
An isotope label was introduced into N-glycosylated sample peptides with PNGaseF in H218O 
buffer. PNGaseF deglycosylates Asn-linked glycopeptides and converts the corresponding Asn 
to Asp. In the presence of H218O buffer 18O is incorporated into the carboxyl-group of the newly 
formed Asp(18, 19). The added standard peptides were synthesized according to the transferrin 
and α1-antitrypsin N-glycosylation site sequences with either Asn or Asp introduced into the N-
glycosylation sequon. The precursor and fragment ion pairs used for each MRM transition were 
selected empirically based on maximal signal intensities and signal specificities as judged from 
the chromatography of extracted ion pairs (Table 2). For the sample peptides, the corresponding 
precursor ion and fragment ion types as selected for the standard peptides were used. The 
inclusion of the standard peptides facilitated the identification and quantitation of N-
glycosylation site occupancy with LC-MS/MS. The peptide mixture was separated on a reverse-
phase nanoLC column and introduced to the mass spectrometer via a nanoelectrospray ion 
source. The chromatography was monitored from the total ion chromatogram (Fig. 2). MRM 
transitions for each target peptide and the fragment ion spectra of the corresponding sample 
peptides were recorded sequentially. The acquisition was grouped into three time periods 
according to the elution positions of the second and the first transferrin target peptides and the 
elution positions of the α1-antitrypsin target peptides, respectively (Fig. 2). 
 
Figure 2 
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The MRM transitions together with the co-elutions of the sample peptides with the labeled 
standard peptides served as primary criteria for peptide identification. In addition, the enhanced 
product ion spectra of the sample peptides were acquired and the peptide sequences were 
deduced from the fragment spectra by comparison with previously recorded fragment ion spectra 
of the corresponding standard peptides (Fig. 3). 
 
Figure 3 
 
Figure 4 
 
The average signal intensities of the sample and standard peptides were used to calculate the site 
occupancies of each glycosylation site (Fig. 4). Overall, the sensitivity for detection of each 
peptide was depending on their ionization characteristics, and was partially accounted for in 
adjusted dwell times of the respective MRM transition (between 20 and 200 ms, Table 2). The 
results are summarized in Table 3. The site occupancy for all detected N-glycosylation sites in 
the healthy control samples ranged between 98 and 100%. The transferrin glycosylation sites are 
equally occupied under normal physiological conditions. In α1-antitrypsin, the first and the third 
N-glycosylation sites were always occupied to 100%, whereas the second N-glycosylation site 
appeared slightly less stringently occupied with an average of 99 ± 1.4% under normal 
physiological conditions. 
The level of site occupancy in CDG-I samples was decreased to variable extents depending on 
the of N-glycosylation sites analyzed. In transferrin, the first N-glycosylation site was occupied 
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from 70% to 96%, whereas the occupancy of second N-glycosylation site was reduced down to 
41% in CDG-I samples (Table 3). Generally, the second transferrin glycosylation site was less 
occupied than the first site, indicating a preferred glycosylation of the first site in this 
glycoprotein. The underglycosylation level of α1-antitrypsin was less pronounced than that of 
transferrin in CDG-I. In α1-antitrypsin, the second N-glycosylation site showed the strongest 
reduction, down to 65% occupancy, whereas the first and third sites were hardly altered, showing 
occupancies between 94-100% and 89-100%, respectively (Table 3). The site occupancy of the 
first α1-antitrypsin N-glycosylation site could not be determined in every sample, possibly due 
to low ionization efficiencies of the triply charged peptide in the ion source. Additionally, this 
peptide contains N-terminal glutamine, which can circularize to pyroglutamic acid and a 
methionine residue which can oxidize to methionine sulfoxide, thus evading detection via the 
MRM transitions applied. The occupancy of transferrin N-glycosylation sites in HFI and in 
alcohol abuse samples were not as pronounced as in CDG-I samples, yet like in CDG-I, the 
second site was less glycosylated than the first one. The N-glycosylation of α1-antitrypsin was 
hardly reduced in the HFI and alcohol abuse samples investigated (Table 3). As expected, N-
glycosylation site occupancy was unchanged in CDG-II samples, which are characterized by 
defects of glycan trimming and elongation. The N-glycosylation site occupancies of transferrin 
and α-1-antitrypsin were determined with high precision as illustrated by the standard deviations 
obtained. The maximum deviation reached 10.8 % in one out of the 28 serum samples analysed. 
The standard deviations calculated for the other samples ranged from 0.0 to 7.8 % per 
glycosylation site. The highest accuracy was obtained in the CDG-II, HFI, alcohol abuse and 
healthy control samples. In these samples the maximum standard deviation was calculated to be 
2.5 % (Table 3). The reasons for the higher deviations in the measurements of the N-
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 13
glycosylation site occupancies of the CDG-I sera are not clear. Possibly, lower serum protein 
levels as observed in CDG-I patients contribute to this observation. 
 
Table 3 
 
From all N-glycosylation sites investigated the second transferrin site appeared to respond most 
sensitively to defects of glycosylation. Clinical information was available for 11 CDG-I cases 
investigated here and we grouped these cases into three groups of patients displaying severe, 
moderate and mild clinical manifestation(11). A clear correlation between the occupancy of the 
second transferrin N-glycosylation site and the severity of CDG-I condition could be observed 
(Fig. 5). The lowest level of site occupancy detected in CDG-I samples never reached less than 
40%. A minor reduction of N-glycosylation site occupancy to about 85% of normal levels as 
seen in transferrin was already compatible with a disease state, indicating that N-glycosylation 
site occupancy is stringently required for proper physiological function of glycoproteins. 
 
Figure 5 
 
Discussion 
Routinely, isoelectric focusing gel electrophoresis of transferrin is applied for the diagnosis of 
CDG. Individual transferrin glycoforms are separated according to charge as mediated by 
terminal sialic acid residues attached to the complex type N-glycans. In combination with 
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Western blotting analysis of transferrin, CDG-I and -II can be easily discriminated. Potential 
transferrin peptide polymorphisms can be revealed by sialidase treatment prior to IEF. 
Additional molecular weight determinations of transferrin by ESI-MS or SELDI-MS can further 
corroborate the diagnosis(7, 8). However, these indirect approaches do not discriminate between 
individual N-glycosylation sites and quantitative information relies on densitometric 
measurements of glycoprotein bands in IEF or SDS-PAGE. In this study we developed a method 
for directly determining the presence and absence of N-glycosylation site occupancy and fine 
deviations from normal N-glycosylation site occupancy could be determined. 
In a small survey we analyzed sera from healthy individuals and authentic serum samples from 
patients suffering from disease conditions associated with reduced N-glycosylation site 
occupancy. We used MRM LC-MS/MS, which allows for sensitive and specific detection of 
target peptides by taking advantage of the dynamic quantitative range capabilities inherent of 
quadrupole mass analyzers(13, 20). Target peptides can be detected and quantified reliably even 
in complex mixtures. Additional confidence in peptide sequence assignment is provided by 
acquisition of enhanced product ion spectra in the ion trapping mode of the quadrupole ion trap 
mass spectrometry (QTRAP) system used. For the first time using this approach, we 
quantitatively mapped N-linked glycosylation sites of selected serum glycoproteins. A striking 
feature of the glycoproteins analyzed, transferrin and α1-antitrypsin, is the narrow range of N-
glycosylation site occupancy under physiological conditions. To warrant normal physiological 
function N-glycosylation site occupancy of 99% and 100% is preserved. Symptomatically mild 
CDG cases show only a slight reduction in N-glycosylation site occupancy, indicating a small 
threshold from healthy to pathological conditions. 
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Our data show a tendency of preferential glycosylation of the first N-linked glycosylation sites in 
transferrin and α1-antitrypsin under conditions of limited dolichol-linked oligosaccharide 
substrate availability. In addition, transferrin was more prone to underglycosylation than α1-
antitrypsin. The reasons for this observation are not clear. Transferrin is about four times more 
abundant in human serum and almost two fold larger than α1-antitrypsin, which might require 
different subsets of the translation and glycosylation machinery in the cell(21).  
Of all N-glycosylation sites analyzed the second transferrin site showed the greatest dynamics in 
site occupancy in pathological conditions. This feature could be exploited for the development of 
an assay targeting the second transferrin site and might be applied in a postnatal screen upon 
suspicion of CDG-I. Information about the glycosylation site occupancy at this stage would be 
beneficial in providing estimates about the developmental prospects of the affected individuals. 
With the clinical information available, we classified CDG-I samples according to previously 
suggested criteria for mild clinical expressions of this disease(11). The remaining samples were 
grouped into moderate and severe clinical expressions. Most samples analyzed were derived 
from patients with a moderate pathology, comprising the classical CDG-I symptoms like failure 
to thrive, seizures, developmental delay, hypotonia, ataxia, or mental regression. The severe 
cases comprised conditions such as death in early childhood in addition to the moderate CDG-I 
pathology. When plotted against the N-glycosylation site occupancy, we found a clear 
correlation between the presence of glycosylation and clinical expression of the disease, 
confirming the causative coherency of the absence of N-glycosylation and clinical expression in 
CDG-I. These findings underline the significance of N-glycosylation in health and development 
of the human organism. Overall, our data validate transferrin as a sensitive marker protein for 
CDG-I and alcohol abuse conditions. The method developed in this study will be useful for 
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unambiguously mapping the sensitivity of proteins to defects of glycosylation. Furthermore, this 
method can be extended by including additional serum glycoproteins, which will contribute to 
better understand the significance of N-glycosylation in human physiology. 
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Figure legends 
 
Figure 1. Isoelectric focusing of selected serum transferrin samples. 
The profile of a serum sample derived from a patient with a severe form of CDG-Ia is shown in 
lane 11. Profiles of moderate CDG-Ia samples are shown in lanes 2, 3, 8, 9, 10. Profiles of mild 
CDG-Ia samples are shown in lanes 7 and 12. Lane 1 shows the profile of a moderate CDG-Ic 
serum. Lane 4 shows a profile from serum of a patient with hereditary fructose intolerance (HFI), 
lane 5 shows the profile of a CDG-IIx serum and lane 6 shows the serum profile of a transferrin 
polymorphism. Samples from healthy control serum are shown in lanes HC. The numbers C0 to 
C6 indicate the number of charges as mediated by sialic acid residues of the transferrin bi- and 
tri-antennary N-glycans. 
 
Figure 2. Total ion chromatogram of a typical MRM-LC-MS/MS run. 
The total ion chromatogram acquisition is divided into three time periods. Peptides 
corresponding to the second transferrin glycosylation site (TFP2) elute within the first period and 
peptides corresponding to the first transferrin glycosylation site (TFP1) elute during the second 
period. MRM transitions and fragment ion spectra corresponding to the α1-antitrypsin N-
glycosylation sites (ATP1-3) are recorded during the third period starting at 50 min. 
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Figure 3. Enhanced product ion spectra (EPI) of a standard and a sample peptide. 
The upper panel shows the EPI spectrum of the synthetic standard peptide TFP1DK 
corresponding to the first, previously occupied transferrin glycosylation site. The lower panel 
shows the EPI spectrum of the corresponding sample peptide sequence as recorded during a LC-
MS run. Major fragment ions referring to the a-, b- and y-series are assigned and the isotopically 
labeled amino acids underlined in the depicted peptide sequences. The isotopic label in the 
sample peptide results from the N-glycanase digestion in H218O containing buffer. For this 
peptide pair the N-terminal fragment ions b3, a4 and b4 are identical whereas the recorded y-type 
fragment ions are mass shifted according to the introduced amino acid isotope differences. The 
major y9-fragment ion was used for the MRM transition for this peptide pair. 
 
Figure 4. Extracted ion chromatogram (XIC) of the MRM transitions of two peptide pairs 
recorded during the second period. 
The standard peptide TFP1DKS (solid line) together with the corresponding sample peptide 
(dotted line) and the standard peptide TFP1NKS (dashed line) are shown in the upper panel. 
Average signal intensities are depicted in histogram of the lower panel and were used for 
calculating N-glycosylation site occupancy. The average MRM signal intensities of the eluting 
peaks at 29 min are shown. The peptide pair referring to the TFP1DK peptide co-elutes with the 
TFP1DKS pair in the chromatography, resulting in the MRM signal bars Sample/TFP1DK at the 
same elution time. 
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Figure 5. Transferrin glycosylation site occupancy versus clinical presentation. 
Clinical information was available for nine CDG-Ia patients, one CDG-Ic patient and one patient 
of unknown CDG-I defect. The samples were classified according to the clinical expression of 
individual patients into severe, moderate and mild forms of CDG-I. The occupancy of the second 
transferrin N-glycosylation site is plotted for each patient in the allocated group. The control 
group contains the values obtained from nine healthy individuals. 
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Table 1. Custom synthesized standard peptides. 
Isotopically labeled amino acids are bold, underlined, F: +10Da, P: +6Da, L: +7Da, A: +4Da. 
Designation Sequence Q3 ion 
ATP1N QLAHQSNSTNIFFSPVSIATAFAMLSLGTK y9 
ATP1D QLAHQSDSTNIFFSPVSIATAFAMLSLGTK y12 
ATP2N DEILEGLNFNLTEIPEAQIHEGFQELLR y2+14 
ATP2D DEILEGLNFDLTEIPEAQIHEGFQELLR y2+14 
ATP3N YLGNATAIFFLP y1 
ATP3D YLGDATAIFFLP b11 
TFP1NK CGLVPVLAENYNK y9 
TFP1NKS CGLVPVLAENYNKS y10 
TFP1DK CGLVPVLAENYDK y9 
TFP1DKS CGLVPVLAENYDKS y10 
TFP2NVT QQQHLFGSNVT b5-NH3 
TFP2DVT QQQHLFGSDVT b9 
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Table 2. Triple quadrupole settings for the target peptides. 
Q1 and Q3 represent the m/z values of the precursor ions with the corresponding fragment ions 
selected for the MRM transitions. The fragmentation conditions for each standard peptide were 
optimized empirically for maximum signal intensities. Dwell = time per transition, DP = 
declustering potential, EP = entrance potential, CEP = collision cell entrance potential, CE = 
collision energy, CXP = collision cell exit potential 
Designation Q1 Q3 Dwell 
(ms) 
DP 
(V) 
EP 
(V) 
CEP 
(V) 
CE 
(V) 
CXP 
(V) 
ATP1N 1064.56 977.56 200 35 9.5 55 44 7 
ATP1D 1066.89 1220.68 200 35 9.5 60 50 49 
ATP2N 1091.89 836.94 200 46 7.5 55 45 6 
ATP2D 1093.56 833.93 200 43 9.0 60 45 6 
ATP3N 667.37 116.07 50 21 7.0 37 27 50 
ATP3D 1337.72 1222.66 20 85 9.5 40 45 50 
TFP1NK 742.39 1054.56 100 40 9.0 40 41 45 
TFP1NKS 785.90 1141.60 100 41 9.5 43 44 48 
TFP1DK 744.88 1059.56 100 41 9.0 40 41 45 
TFP1DKS 788.40 1146.59 100 41 9.5 43 44 48 
TFP2NVT 633.32 625.29 150 40 9.0 35 37 43 
TFP2DVT 635.32 1051.50 150 40 9.0 35 37 44 
. 
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Table 3. N-glycosylation site occupancy of transferrin and α1-antitrypsin. 
Values for each glycosylation site are averaged and given in percentage site occupancy. Standard 
deviations are given for sites where three or more values were averaged (SD with n≥3). The values 
for the healthy control are averaged from MRM-LC-MS/MS runs of nine individual serum samples. 
Group Gene defect OMIM entry   TFP1D1 TFP2D1 ATP1D1 ATP2D1 ATP3D1
Healthy    average: 99 99 100 99 100 
 controls     SD (n=3-14) 1.1 0.7 0.0 1.4 0.2 
CDG-Ia PMM2 601785 average: 96 94 100 97 100 
      SD (n=3) 3.3    0.0 
CDG-Ia PMM2 601785 average: 89 75 100 100 98 
      SD (n=3-6) 3.3 0.9 0.0 0.0 1.2 
CDG-Ia PMM2 601785 average: 70 59 100 94 96 
      SD (n=3-6) 4.2 3.7   2.0 
CDG-Ia PMM2 601785 average: 72 41 94 65 94 
      SD (n=3-5) 10.8 6.2 10.8 5.4 4.0 
CDG-Ia PMM2 601785 average: 88 56 100 92 98 
      SD (n=3-4) 5.2 4.5 0.0 2.3 2.2 
CDG-Ia PMM2 601785 average: 72 41 98 82 90 
      SD (n=3-4) 4.2 2.1   3.8 
CDG-Ia PMM2 601785 average: 95 89 100 99 99 
      SD (n=3) 3.3    0.6 
CDG-Ia PMM2 601785 average: 79 67 100 100 95 
      SD (n=3-4) 2.0 2.4   2.3 
CDG-Ia PMM2 601785 average: 91 76  94 98 
      SD (n=4) 2.9 2.3   0.5 
CDG-Ib MPI   154550 average: 93 91 100 97 99 
      SD (n=3-4) 2.8   0.4 0.3 
CDG-Ic ALG6 604566 average: 90 62 100 100 93 
      SD (n=4) 1.8 2.5   2.2 
CDG-Ic ALG6 604566 average: 83 57 99 79 89 
      SD (n=3-4) 4.4 7.8   2.3 
CDG-Ie DPM1   603503 average: 91 85 100 99 99 
      SD (n=3) 2.8    0.2 
CDG-If MPDU1   604041 average: 92 85  92 98 
      SD (n=4-5) 1.1 1.7   0.7 
CDG-Ix unknown  average: 86 79 98 95 98 
      SD (n=3) 9.3    2.0 
CDG-IIa MGAT2   602616 average: 99 97 100 99 100 
      SD (n=4-5) 0.2 1.7 0.2 0.2 0.3 
CDG-IIx unknown  average: 100 98  99 100 
      SD (n=3-4) 0.0 0.3  0.1 0.1 
HFI ALDOB 229600 average: 96 91 100 98 99 
      SD (n=3-4) 0.9 2.5 0.1 1.8 0.2 
Alcohol 
abuse 
aquired  average: 96 91 100 97 99 
    SD (n=4-5) 1.3 1.4 0.0 0.9 0.2 
1 TFP1D, first transferrin N-glycosylation site; TFP2D, second transferrin N-glycosylation site; 
ATP1D, first α1-antitrypsin N-glycosylation site; ATP2D, second α1-antitrypsin N-glycosylation site; 
ATP3D, third α1-antitrypsin N-glycosylation site. 
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Figures 
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